Cases & Deals

  • Home
  • Practices
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to Tolmar

Share

Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to Tolmar

January 2021

Client(s) Astellas Pharma Inc.

Jones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited. Tolmar concurrently licensed the rights to commercialize Eligard® in Europe, Turkey, Russia and other territories to Recordati Industria Chimica e Farmaceutica S.p.A. As a result of the transactions, Recordati is taking over the Astellas position as Eligard® licensee in these territories.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.